About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/16/2021.

Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine

Clinicaltrials.gov identifier NCT03927131

Recruitment Status Not yet recruiting

First Posted April 25, 2019

Last update posted October 16, 2019

Study Description

Brief summary:

Studies have showed that a broader spectrum influenza vaccine may help in reducing the influenza burden of disease. Butantan Institute is currently developing a quadrivalent influenza vaccine candidate. This study is will provide safety and immunogenicity data on this quadrivalent influenza vaccine candidate. The study will be conducted in an open population of healthy participants (3-59 years old) recruited in different clinical sites in Brazil and will be adequately powered to assess safety, immune response (measured by GMT HI antibodies) to each viral strain in the vaccines and lot-to-lot consistency.

  • Condition or Disease:Influenza
  • Intervention/Treatment: Biological: QIV-IB
    Biological: TIVV-IB
    Biological: TIVY-IB
    Biological: QIV-IB Lot A
    Biological: QIV-IB Lot B
    Biological: QIV-IB Lot C
  • Phase: Phase 3
Detailed Description

This is a double blinded, randomized active-control comparator study to assess the safety and immunogenicity of QIV-IB, the Butantan Institute quadrivalent influenza vaccine candidate. As active controls, two trivalent influenza vaccines with different Influenza B strains, one with influenza B/Victoria strain (TIVV-IB) and other with influenza B/Yamagata strain (TIVY-IB) The study is designed to build a safety database of the quadrivalent influenza vaccine in adults to detect adverse events with a frequency of 1:1000 or higher and safety databases for pediatric age groups to detect adverse events with frequency of 1:100 or higher. In terms of immune response, the study aims to demonstrate superiority of HI (Hemagglutinin inhibition) GMT (Geometric Mean Titer) of the QIV-IB for the Influenza B strain that is not present in each trivalent vaccine control. Regarding the Influenza A and B strains common to QIV-IB and both trivalent vaccine controls, the study aims to demonstrate non-inferiority on those strains. Finally, a lot-to-lot consistency test will be performed in a sub-group of adult participants.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 6018 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Primary Purpose: Prevention
  • Official Title: Double-blind, Randomized Clinical Trial With Active Controls to Assess Safety, Immunogenicity and Lot-to-lot Consistency of Inactivated Split-virion Quadrivalent Influenza Vaccine of Butantan Institute
  • Estimated Study Start Date: April 2020
  • Estimated Primary Completion Date: December 2020
  • Estimated Study Completion Date: December 2020
Arms and interventions
Arm Intervention/treatment
Experimental: QIV-IB
Inactivated split-virion quadrivalent influenza vaccine
Biological: QIV-IB
Inactivated split-virion quadrivalent influenza vaccine
Active Comparator: TIVV-IB
Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Victoria lineage
Biological: TIVV-IB
Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Victoria lineage
Active Comparator: TIVY-IB
Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Yamagata lineage
Biological: TIVY-IB
Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Yamagata lineage
Experimental: QIV-IB Lot A
Inactivated split-virion quadrivalent influenza vaccine - Lot A
Biological: QIV-IB Lot A
Inactivated split-virion quadrivalent influenza vaccine - Lot A
Experimental: QIV-IB Lot B
Inactivated split-virion quadrivalent influenza vaccine - Lot B
Biological: QIV-IB Lot B
Inactivated split-virion quadrivalent influenza vaccine - Lot B
Experimental: QIV-IB Lot C
Inactivated split-virion quadrivalent influenza vaccine - Lot C
Biological: QIV-IB Lot C
Inactivated split-virion quadrivalent influenza vaccine - Lot C
Outcome Measures
  • Primary Outcome Measures: 1. Safety of QIV-IB per age group [ Time Frame: 42 days post-vaccination ]
    Frequency and intensity of adverse events reactions and events of special interest
  • 2. Superiority for influenza B/Victoria strain [ Time Frame: 21 days post-vaccination ]
    HI GMT ratio for Influenza B/Victoria strains between QIV-IB and TIVY-IB
  • 3. Superiority for influenza B/Yamagata strain [ Time Frame: 21 days post-vaccination ]
    HI GMT ratio for Influenza B/Yamagata strains between QIV-IB and TIVY-IB
  • 4. Non-inferiority for common influenza strains between QIV-IB, TIVV-IB and TIVV-IB [ Time Frame: 21 days post-vaccination ]
    HI GMT ratios for Influenza strains between QIV-IB, TIVV-IB and TIVV-IB
  • 5. Lot-to-lot consistency for immune response to different lots of QIV-IB [ Time Frame: 21 days post-vaccination ]
    HI GMT ratios for Influenza strains between QIV-IB, TIVV-IB and TIVV-IB
Eligibility Criteria
  • Ages Eligible for Study: 3 to 59 Years (Child, Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: Yes
Criteria

Inclusion Criteria:

- Male or female, age 3 to 59 years (inclusive) at the time of enrollment.

- Provide written informed consent

- Agrees to complete all study visits, procedures and contacts

- Women and adolescents of childbearing age: Negative pregnancy test with understanding
(through informed consent process).

Exclusion Criteria:

- Chronic medical conditions such as psychiatric conditions, diabetes, hypertension or
any other conditions that might place the subjects at high risk of adverse events.
Study clinicians will use clinical judgment on a case-by-case basis to assess safety
risks under this criterion.

- Clinically significant abnormalities on physical examination.

- Use of immunosuppressive medications such as systemic corticosteroids or
chemotherapeutics, or immunosuppressive illness.

- Women who are pregnant or planning to become pregnant during the study period plus 3
months beyond the last vaccine dose and currently nursing women.

- Participation in research involving another investigational product within 30 days
before planned date of first vaccination or anytime through the last study safety
visit.

- Clinically significant abnormalities on basic laboratory screening tests.

- Acute febrile illness (axillar temperature ≥ 37.8°C)

- Hypersensitivity to egg or chicken proteins or any of the vaccine constituents

- Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination

- Unstable chronic illness (defined as illness requiring hospitalization or a clinically
significant change in medication in the previous 12 weeks).

- Alcohol abuse of alcohol or drug addiction

- Any vaccination within the previous 4 weeks For immune response groups

- Seasonal influenza vaccination in the previous or current years

Contacts and Locations
Contacts

Contact: Ricardo Palacios, MD, PhD +55 11 3723-2121 ricardo.palacios@butantan.gov.br

Locations
Sponsors and Collaborators

Butantan Institute

Fundação Butantan

Investigators

Study Director: Ricardo Palacios, MD, PhD Instituto Butantan

More Information
  • Responsible Party: Butantan Institute
  • ClinicalTrials.gov Identifier: NCT03927131 History of Changes
  • Other Study ID Numbers: FLQ-01-IB
  • First Posted: April 25, 2019 Key Record Dates
  • Last Update Posted: October 16, 2019
  • Last Verified: October 2019
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Butantan Institute: Vaccine
  • Additional relevant MeSH terms: Influenza, Human